Category: Press Release

2020.11.13

I-Mab to Hold Investor Call and Expand Clinical Data Analysis on Efficacy Signal of Lemzoparlimab from Phase 1 Clinical Trial

2020.11.11

I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020

2020.11.09

I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting

2020.10.28

I-Mab Announces Upcoming Participation at November Conferences

2020.10.27

I-Mab to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

2020.10.15

I-Mab to Present Phase 1 Data of Lemzoparlimab at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

2020.09.30

I-Mab Receives China CDE Approval to Initiate Phase 3 Clinical Trial of Eftansomatropin in Pediatric Patients with Growth Hormone Deficiency

2020.09.21

I-Mab Announces China NMPA Clearance for Phase 1 Clinical Trial of Lemzoparlimab in Relapsed or Refractory Advanced Lymphoma

2020.09.17

MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer

2020.09.08

I-Mab Announces Upcoming Participation at September Conferences